297 related articles for article (PubMed ID: 37322116)
1. Intratumoral dendritic cell-CD4
Magen A; Hamon P; Fiaschi N; Soong BY; Park MD; Mattiuz R; Humblin E; Troncoso L; D'souza D; Dawson T; Kim J; Hamel S; Buckup M; Chang C; Tabachnikova A; Schwartz H; Malissen N; Lavin Y; Soares-Schanoski A; Giotti B; Hegde S; Ioannou G; Gonzalez-Kozlova E; Hennequin C; Le Berichel J; Zhao Z; Ward SC; Fiel I; Kou B; Dobosz M; Li L; Adler C; Ni M; Wei Y; Wang W; Atwal GS; Kundu K; Cygan KJ; Tsankov AM; Rahman A; Price C; Fernandez N; He J; Gupta NT; Kim-Schulze S; Gnjatic S; Kenigsberg E; Deering RP; Schwartz M; Marron TU; Thurston G; Kamphorst AO; Merad M
Nat Med; 2023 Jun; 29(6):1389-1399. PubMed ID: 37322116
[TBL] [Abstract][Full Text] [Related]
2. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
[TBL] [Abstract][Full Text] [Related]
3. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells.
Balança CC; Salvioni A; Scarlata CM; Michelas M; Martinez-Gomez C; Gomez-Roca C; Sarradin V; Tosolini M; Valle C; Pont F; Ferron G; Gladieff L; Vergez S; Dupret-Bories A; Mery E; Rochaix P; Fournié JJ; Delord JP; Devaud C; Martinez A; Ayyoub M
JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33332284
[TBL] [Abstract][Full Text] [Related]
4. Progenitor-like exhausted SPRY1
Liu Z; Zhang Y; Ma N; Yang Y; Ma Y; Wang F; Wang Y; Wei J; Chen H; Tartarone A; Velotta JB; Dayyani F; Gabriel E; Wakefield CJ; Kidane B; Carbonelli C; Long L; Liu Z; Su J; Li Z
Cancer Cell; 2023 Nov; 41(11):1852-1870.e9. PubMed ID: 37832554
[TBL] [Abstract][Full Text] [Related]
5. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
6. Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors.
Khan SM; Desai R; Coxon A; Livingstone A; Dunn GP; Petti A; Johanns TM
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543376
[TBL] [Abstract][Full Text] [Related]
7. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer.
Bassez A; Vos H; Van Dyck L; Floris G; Arijs I; Desmedt C; Boeckx B; Vanden Bempt M; Nevelsteen I; Lambein K; Punie K; Neven P; Garg AD; Wildiers H; Qian J; Smeets A; Lambrechts D
Nat Med; 2021 May; 27(5):820-832. PubMed ID: 33958794
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of tumor-reactive CD4
Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331
[TBL] [Abstract][Full Text] [Related]
9. PD1
Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
11. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma.
Cheng Y; Gunasegaran B; Singh HD; Dutertre CA; Loh CY; Lim JQ; Crawford JC; Lee HK; Zhang X; Lee B; Becht E; Lim WJ; Yeong J; Chan CY; Chung A; Goh BKP; Chow PKH; Chan JKY; Ginhoux F; Tai D; Chen J; Lim SG; Zhai W; Choo SP; Newell EW
Immunity; 2021 Aug; 54(8):1825-1840.e7. PubMed ID: 34270940
[TBL] [Abstract][Full Text] [Related]
12. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
13. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
14. Lack of CD8
Horton BL; Morgan DM; Momin N; Zagorulya M; Torres-Mejia E; Bhandarkar V; Wittrup KD; Love JC; Spranger S
Sci Immunol; 2021 Oct; 6(64):eabi8800. PubMed ID: 34714687
[TBL] [Abstract][Full Text] [Related]
15. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
16. PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells.
Viramontes KM; Neubert EN; DeRogatis JM; Tinoco R
Front Immunol; 2022; 13():869768. PubMed ID: 35774790
[TBL] [Abstract][Full Text] [Related]
17. Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions.
Garcia-Bates TM; Palma ML; Shen C; Gambotto A; Macatangay BJC; Ferris RL; Rinaldo CR; Mailliard RB
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541848
[TBL] [Abstract][Full Text] [Related]
18. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
19. CD28/PD1 co-expression: dual impact on CD8
Palermo B; Franzese O; Frisullo G; D'Ambrosio L; Panetta M; Campo G; D'Andrea D; Sperduti I; De Nicola F; Goeman F; Gallina F; Visca P; Facciolo F; Nisticò P
J Exp Clin Cancer Res; 2023 Oct; 42(1):287. PubMed ID: 37898752
[TBL] [Abstract][Full Text] [Related]
20. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]